glp-1 and dpp4 receptor agonists are increasingly used to treat type 2 diabetes obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal. Read status:live-noLabs-noHCC Plan Option:Every 6 months Evidence that physiological metabolic

glp-1 and dpp4 receptor agonists are increasingly used to treat type 2 diabetes obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal. Read status:live-noLabs-noHCC Plan Option:Every 6 months Evidence that physiological metabolic

Evidence that physiological metabolic actions of GLP-1 are dependent on... | Download Scientific Diagram

[DOI] [PMC free article] [PubMed] [Google Scholar] 33.Garvey W.T., Batterham R.L., Bhatta M., et al

status:live-noLabs-noHCC

Plan Option:Every 6 months

However, the permanence of this weight loss can depend on long-term follow-up and lifestyle modifications